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Malaria is a public health problem in French Guiana. Plasmodium vivax is the most frequent parasite. The objective
of this analysis was to estimate the proportion of relapses in the burden of vivax malaria using the statistical rule
stating that any case of vivax malaria occurring less than 90 days following a first episode is a relapse.
A total of 622 subjects were followed for 2,9 years with 336 first single episodes of P. vivax malaria, and a total of
1,226 episodes of vivax malaria among which 559 were relapses (45.5%). For 194 patients having had falciparum
malaria followed by vivax malaria it was estimated that 19% of the vivax episodes occurred less than 90 days
following the falciparum episode and thus were possibly relapses due to the activation of latent hypnozoites.
Despite the number of vivax cases and the number of relapses, there were only 28 recorded primaquine
prescriptions (3.4% of vivax episodes, 4.5% of subjects).
The present study points out that despite the fact that nearly half of the P. vivax cases, many of which in children,
are caused by latent hypnozoites, only a minority of them benefit from primaquine radical cure. The obstacles to
this are discussed and suggestions are made to reduce the burden of vivax malaria in Camopi and other remote
health centres in French Guiana.Background
Malaria remains a public health problem in French
Guiana, a French overseas territory in South America
[1-3]. Ninety four percent of the territory is covered by
rainforest. Due to a combination of interventions, the
visible part of malaria incidence has decreased to a total
of around 800 cases a year in 2012. Malaria mostly
affects around 30,000 persons living in remote areas and
10,000-15,000 garimpeiros living in the forest [4]. Much
of the malaria problem originates from this last group
that is out of the reach of the health system and makes
malaria elimination elusive [5]. Before 2008, there were
mines 15 km from Camopi. Since the Harpie operations
from the French armed forces started in 2008, the closest
mines are at least 30 km from Camopi. Garimpeiros do
not stay in Camopi, but they may stay in the neighbouring* Correspondence: mathieu.nacher66@gmail.com
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reproduction in any medium, provided the ortown across on the Brazilian side. However, some of the
persons living in Camopi are involved in supplying mining
sites where they may get infected. Between 2001 and
2009, in a cohort of Amerindian children in Camopi, a
village on the Eastern border of French Guiana, the
overall annual incidence rates of Plasmodium vivax
malaria were 514 per 1,000 persons for single infections,
and 21 per 1,000 persons for mixed infections [1]. The
P. vivax incidence varied between 300 per 1,000 persons
and 935 per 1,000 persons. Recently, data was presented
suggesting that, in French Guiana, an interval under
90 days between two P. vivax infections was most likely
a relapse, whereas over 90 days it was presumed to be a
re-infection [6]. In French Guiana, there have been specific
logistical and legal difficulties for the effective delivery of a
radical cure by targeting hypnozoites with primaquine.
The objective of the present study was to better describe
the issue of relapses in this cohort, and its potential
implications.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study site
The study took place in Camopi, an Amerindian village
in the Amazon forest along the Oyapock River, which
delineates the border with Brazil. A retrospective open
cohort study was carried out with data from all children
born between January 1, 2001 and December 31st 2011.
The children come to the health centre approximately
once a month, generally for treatment or for prevention
(i.e. vaccination). Every six months, a researcher verifies
that all newborn children are included in the cohort,
that all children are present in the village, and that all
the malaria data is collected. Data for children for whom
follow-up by the health centre had been interrupted was
right censored at the interruption date. Given the isolation
of Camopi and the fact that malaria diagnosis and health
care is delivered free of charge, it was assumed that all
malaria cases were recorded by the health centre.
There has been a recent malaria decline which was
concomitant with a number of events: (i) the distribu-
tion of rapid diagnostic tests, starting in 2007, clearing
the vegetation around homes starting in 2007(2); (ii)
the “Harpie operation” involving over 1,000 soldiers
and military police, which have, since March 2008, dis-
mantled illegal mining sites, sent back arrested miners
to their country, and destroyed on-site mining equip-
ment, with possible effects on malaria transmission;
(iii) insecticide-treated bed nets started being distrib-
uted in 2010; and (iv) the creation of the regional health
agency which led to an intensification of trans-border
cooperation.Figure 1 Annual number of vivax malaria cases in Camopi, French GuMalaria diagnosis
All clinical malaria episodes, their date of occurrence,
Plasmodium species identification were made in the
Camopi health centre. Blood smears were first analysed
in Camopi by a trained nurse and then cross-checked by
the Parasitology Unit of Cayenne General Hospital, the
reference centre for parasitological diagnosis in French
Guiana. Malaria was defined as temperature > 38°C at the
time of consultation or fever within the past 48 hours
associated with Plasmodium asexual forms on a thin
blood smear (detection threshold: 50 Plasmodium/μl). The
treatment prescribed was also collected in the medical
records.
Treatment
During the study period, all confirmed cases of P. vivax
received an unsupervised three-day treatment of chloro-
quine (total 25 mg/kg). In Camopi, treatment with a com-
bination of primaquine (14 days) and chloroquine (3 days)
was supposedly initiated in 2005, following a first relapse.
This prescription of primaquine implies respecting French
prescription rules: systematic screening for G6PD defi-
ciency (contra-indication if case of G6PD deficiency)
this is performed in Cayenne and thus leads to delays in
obtaining results; in addition prescription requires a
nominative temporary use authorization from the state
drug authority, which requires paperwork by the physician
and delays between the transmission of the paperwork
and the authorization. This procedure has been simplified
in 2012 to reduce prescription delays. For primaquine
prescription, the data from the medical records wasiana.
Figure 2 Number of cases and incidence of Plasmodium vivax malaria by age group (2001-2011).
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benefitted from a temporary authorization for the use
of primaquine.Analysis
The number of vivax cases per year was retrieved with a
differentiation between relapses according to the 90-day
criteria (if malaria occurs between 7 and 90 days following
a first episode of vivax, it is a relapse, if it occurs after
90 days it is a new infection). Incidence rates were calcu-
lated by age group, and by year using multiple failure
models. In order to obtain the relapse rate, a graph was
produced based on the fact that the relationship between
the numbers of patients who experience one or more,
two or more, three or more etc relapses is exponentialFigure 3 Theoretical proportion of children concerned by N or moresummarized by the formula xn where x is the fraction
of patients experiencing n relapses [7]).
Ethical and regulatory aspects
All parents were given an explanation and written consent
was obtained for the study. The protocol was approved by
the CCTIRS (Comité Consultatif pour le Traitement des
Informations de Recherche en Santé), and the database
was declared to the Commission Nationale Informatique
et Libertés, the French regulatory authority.
Results
There were 622 subjects followed for a total of 2,9 years
with 336 first single episodes of P. vivax malaria, and a
total of 1,226 episodes of vivax malaria among which
559 were relapses (45.5%). For 194 patients having hadrelapses.
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estimated that 19% of the vivax episodes occurred less
than 90 days following the falciparum episode and, thus,
were possibly relapses due to the activation of latent
hypnozoites.
Figure 1 shows the temporal evolution of vivax malaria
and of relapses in Camopi with a recent significant decline
of malaria incidence. Figure 2 shows the decline of vivax
malaria and relapses according to age. Figure 3 shows the
theoretical and observed proportion of children with n or
more relapses. This showed that the observed data was
closest to the theoretical proportion of 50% of persons
relapsing.
For a total of 1,226 vivax single infections and 559
relapses according to the 90-day criteria in 622 subjects in
Camopi there were 28 recorded primaquine prescriptions
(3.4% of vivax episodes, 4.5% of subjects). In 2011-2012, in
French Guiana, there were approximately 2,000 malaria
cases of which 75% were vivax malaria. During the same
period there were 259 prescriptions of primaquine, thus
30% of the number of reported vivax cases.
Discussion
Although all vivax primary infections do not lead to
subsequent relapses, calculations showed that around
half would lead to subsequent relapses. Similarly, 19%
of patients having had falciparum malaria had a vivax mal-
aria episode within 90 days, suggesting the P. falciparum
infection could have activated latent hypnozoites [7]. In
this remote village, a large proportion of the children’s
vivax malaria burden appeared to be due to relapses. A
large proportion of the illness and perhaps an even larger
proportion of the transmission of vivax malaria are thus
attributable to the activation of latent hypnozoites. The
striking finding was that despite this, primaquine was very
rarely used for a radical cure. Since a consensus conference
in 2002, it was recommended in French Guiana, the high
council for public health of France also recommended it,
notably in endemic areas, at a dose of 0.5 mg/kg/day with
30 mg/day limit for children. However, obviously there are
hurdles that stand in the way of the implementation of
these recommendations. The G6PD test needs to be
performed in Cayenne, samples are shipped by canoe,
followed by a three-hour drive to reach the laboratory.
This is logistically complicated and leads to delayed
results, which is not ideal for patient follow-up. In
addition, the extra paperwork required in order to obtain
official permission to use this drug and the delays between
the demand and the authorization adds more delays, and
possibly leads some physicians to avoid the complications.
Finally, a number of physicians think that it would be
useless to use primaquine in endemic areas and only use
it as terminal prophylaxis when patients come back to live
in an area without malaria. Overall, these complicationsprobably converge towards the non-use of primaquine, a
drug that could theoretically greatly reduce the vivax
problem, in Camopi, and other malaria endemic areas of
French Guiana.
This sobering observation should stimulate to propose
solutions to fix the problem. First, the G6PD problem:
Nearly all pregnant women from remote areas deliver in
one of the three hospitals in French Guiana, including
women from Camopi. Thus, neonates coming from
malaria endemic areas could be easily screened for
G6PD deficiency before hospital discharge, and their
result written in their health book. Another alternative
would be point of care testing, with the possibility of using
Beutler’s fluorescent spot test on site, or to validate rapid
G6PD tests on the field [8,9]. Finally, mass G6PD screening
in Camopi, perhaps coupled with active case detection
could also allow to have the G6PD results for all persons
(Camopi has a population around 1,600). It is perplexing
that this old drug (FDA approved in 1952) still does not
have official approval in France, 61 years later. The high
council for public health could only wish for a pharma-
ceutical company to take on the burden of applying for
approval by the authorities. Given the rarity of malaria in
France, there is no market, and no incentive for pharma-
ceutical companies to start the approval process.
A large portion of the vivax malaria problem in these
Amerindian children is linked to the activation of latent
hypnozoites. Despite research aiming to differentiate pri-
mary infections from relapses [6,10], despite recommen-
dations to use primaquine, this reality does not lead to
changes on the field. Malaria eradication is challenging in
this remote area surrounded by the Amazon forest and
often in contact with illegal gold miners who represent
uncontrolled transmission reservoirs [11]. This is com-
pounded by vivax relapses and the absence of radical cure.
There are some solutions to facilitate the implementation
of standard treatment policy. Authorities should do all they
can to facilitate the prescription of primaquine in French
Guiana. With optimal adherence ensured by supervised
administration in this small village, radical treatment will
improve the situation of a number of individual patients.
New drugs, such as tafenoquine, may improve compliance
and new tests such as field adapted RDT for G6PD may
facilitate prescription.
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